Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to -$31.5 million.

  • C4 Therapeutics' Free Cash Flow fell 3063.43% to -$31.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.8 million, marking a year-over-year decrease of 3241.91%. This contributed to the annual value of -$65.3 million for FY2024, which is 3980.71% up from last year.
  • Latest data reveals that C4 Therapeutics reported Free Cash Flow of -$31.5 million as of Q3 2025, which was down 3063.43% from -$12.1 million recorded in Q2 2025.
  • C4 Therapeutics' 5-year Free Cash Flow high stood at -$5.2 million for Q2 2024, and its period low was -$33.7 million during Q1 2023.
  • Over the past 5 years, C4 Therapeutics' median Free Cash Flow value was -$25.3 million (recorded in 2022), while the average stood at -$23.7 million.
  • In the last 5 years, C4 Therapeutics' Free Cash Flow surged by 7328.89% in 2024 and then crashed by 13316.57% in 2025.
  • C4 Therapeutics' Free Cash Flow (Quarter) stood at -$25.8 million in 2021, then dropped by 18.77% to -$30.6 million in 2022, then grew by 21.07% to -$24.2 million in 2023, then rose by 25.81% to -$17.9 million in 2024, then tumbled by 75.75% to -$31.5 million in 2025.
  • Its last three reported values are -$31.5 million in Q3 2025, -$12.1 million for Q2 2025, and -$33.3 million during Q1 2025.